<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03830567</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB 16158</org_study_id>
    <nct_id>NCT03830567</nct_id>
  </id_info>
  <brief_title>Pharmacists Expand Access to Reproductive heaLthcare</brief_title>
  <acronym>PEARL</acronym>
  <official_title>Pharmacists Expand Access to Reproductive Healthcare: Reducing Unintended Pregnancy Through Pharmacist Prescription of Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laura and John Arnold Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective cohort study of women presenting to initiate hormonal contraception, prescribed
      by a clinician or pharmacist. Women will be followed for one year to assess contraceptive
      continuation and unintended pregnancy rates, as well as measures of safety and acceptability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Direct prescription of hormonal contraception (HC) by pharmacists, without a doctor's visit
      or medical prescription, is a strategy to improve access to contraception and reduce
      unintended pregnancy. Oregon is the first state in the nation to implement legislation, as of
      January 1, 2016, expanding the scope of pharmacists to prescribe short-acting HCs. House Bill
      (HB) 2879 allows pharmacists to directly prescribe HC including the patch and pill, without a
      medical prescription. Women over 18 years of age can either initiate or continue HCs with a
      pharmacist, and women under 18 can continue a prescription.

      This prospective cohort study of women presenting to initiate hormonal contraception,
      prescribed by a clinician or pharmacist, aims to determine contraceptive continuation and
      incident pregnancy rates between women receiving hormonal contraception from a pharmacist
      versus other prescriber. Women will be followed for one year to assess contraceptive
      continuation and unintended pregnancy rates.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 27, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Contraceptive continuation rates</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of contraceptive continuation assessed through survey at 12 months among women who present for contraception in pharmacies.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">471</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Pharmacist prescription</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinician prescription</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacist prescription</intervention_name>
    <description>Pharmacist prescribed hormonal contraception (initiation or continuation).</description>
    <arm_group_label>Pharmacist prescription</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinician prescription</intervention_name>
    <description>Clinician prescribed hormonal contraception (initiation or continuation).</description>
    <arm_group_label>Clinician prescription</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women presenting to initiate hormonal contraception at a study pharmacy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women presenting to initiate hormonal contraception at a study pharmacy

        Exclusion Criteria:

          -  Pregnancy

          -  Contraindications to hormonal contraception

          -  Under 18 years of age

          -  Unable or unwilling to consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria I Rodriguez, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 2, 2019</study_first_submitted>
  <study_first_submitted_qc>February 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2019</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Maria Rodriguez, MD, MPH</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hormonal Contraception</keyword>
  <keyword>Birth Control</keyword>
  <keyword>Pharmacists</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

